Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Heron Therapeutics, Inc.

Heron Therapeutics focuses on developing medicines aimed at addressing unmet medical needs in oncology care and acute pain management. self-described as unwavering in their commitment to improve patients' lives.

Metric
Company Name	Heron Therapeutics, Inc.
Symbol	HRTX
MSH ID	COM:HERONTX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	126
Website	herontx.com
LinkedIn
Founders

Metric
Market Cap	457.99M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	127.04M
Revenue (LTM)
Revenue (NTM)
Gross Profit	61.94M
EBITDA	-107.72M
Operating Income	-110.61M
Net Income	-110.56M
EPS	-0.80
Diluted EPS	-0.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.65
Operating Profit Margin	-0.32
EBITDA Margin	-0.85
Net Profit Margin	-0.33
Return on Equity	3.92
Return on Assets	-0.22
Return on Capital Employed	-0.34

COM:HERONTX

Heron Therapeutics

Last Close

1.06

22/11 21:00

Market Cap

457.99M

Beta: -

Volume Today

1.34M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.57
P/B Ratio	-11.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.40
EV Multiple	-1.86

Metric
Days Sales Outstanding	189.56
Days Payables Outstanding	10.01
Days Inventory Outstanding	332.49
Operating Cycle	529.79
Cash Conversion Cycle	450.46
Asset Turnover	0.67

Metric
Operating Cash Flow	-58.79M
Free Cash Flow	-60.33M
Cash Flow to Debt	-0.09
Operating Cash Flow/Sales	-0.11
Free Cash Flow Yield	-0.30

Metric
Cash & Equivalents	28.68M
Accounts Receivable	-8.09M
Inventory	42.11M
Goodwill
Debt to Capitalization	1.27
Debt to Assets	0.79
Current Ratio	2.43
Quick Ratio	1.90

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.32
R&D to Revenue	0.46
SG&A to Revenue	0.38